Literature DB >> 8550227

Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.

L C Paoletti1, R C Kennedy, T C Chanh, D L Kasper.   

Abstract

Maternal vaccination has been proposed as a rational approach for the prevention of neonatal group B streptococcal (GBS) disease. In this study, baboons were used as a nonhuman primate model to evaluate the immunogenicity of a GBS type III glycoconjugate vaccine. Type III-specific immunoglobulin G with opsonic activity was induced after vaccination with type III polysaccharide coupled to tetanus toxoid administered with an aluminum adjuvant. This suggests that baboons could be used in evaluating maternal transfer of GBS-specific antibodies by vaccination during pregnancy.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8550227      PMCID： PMC173821          DOI： 10.1128/iai.64.2.677-679.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  21 in total

Review 1.  Group B streptococcal infections.

Authors:  C J Baker
Journal:  Adv Intern Med       Date:  1980

2.  Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.

Authors:  T Lagergard; J Shiloach; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

3.  Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci.

Authors:  R S Baltimore; D L Kasper; C J Baker; D K Goroff
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

4.  Immunogenicity of polysaccharides from type III, group B Streptococcus.

Authors:  C J Baker; M S Edwards; D L Kasper
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

5.  Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus.

Authors:  C J Baker; M A Rench; M S Edwards; R J Carpenter; B M Hays; D L Kasper
Journal:  N Engl J Med       Date:  1988-11-03       Impact factor: 91.245

Review 6.  Group B streptococcal vaccines.

Authors:  C J Baker; D L Kasper
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

7.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.

Authors:  C J Baker; D L Kasper
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

8.  Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen.

Authors:  M R Wessels; V Pozsgay; D L Kasper; H J Jennings
Journal:  J Biol Chem       Date:  1987-06-15       Impact factor: 5.157

9.  Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection.

Authors:  C J Baker; M S Edwards; D L Kasper
Journal:  Pediatrics       Date:  1981-10       Impact factor: 7.124

10.  Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus.

Authors:  C J Baker; D L Kasper; A Paredes; S Alpert; W M McCormack; D Goroff
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808
View more
  9 in total

1.  OspE-related, OspF-related, and Elp lipoproteins are immunogenic in baboons experimentally infected with Borrelia burgdorferi and in human lyme disease patients.

Authors:  P Scott Hefty; Chad S Brooks; Amy M Jett; Gary L White; Stephen K Wikel; Ronald C Kennedy; Darrin R Akins
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Comparison and characterization of immunoglobulin G subclasses among primate species.

Authors:  M H Shearer; R D Dark; J Chodosh; R C Kennedy
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

3.  Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.

Authors:  L C Paoletti; M A Rench; D L Kasper; D Molrine; D Ambrosino; C J Baker
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

4.  Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide.

Authors:  Filippo Carboni; Roberto Adamo; Monica Fabbrini; Riccardo De Ricco; Vittorio Cattaneo; Barbara Brogioni; Daniele Veggi; Vittoria Pinto; Irene Passalacqua; Davide Oldrini; Rino Rappuoli; Enrico Malito; Immaculada Y Ros Margarit; Francesco Berti
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 5.  Group B Streptococcus vaccine: state of the art.

Authors:  Annalisa Nuccitelli; C Daniela Rinaudo; Domenico Maione
Journal:  Ther Adv Vaccines       Date:  2015-05

6.  Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides.

Authors:  Simona Gallorini; Francesco Berti; Giuseppe Mancuso; Roberta Cozzi; Marco Tortoli; Gianfranco Volpini; John L Telford; Concetta Beninati; Domenico Maione; Andreas Wack
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-29       Impact factor: 11.205

7.  Lmb, a protein with similarities to the LraI adhesin family, mediates attachment of Streptococcus agalactiae to human laminin.

Authors:  B Spellerberg; E Rozdzinski; S Martin; J Weber-Heynemann; N Schnitzler; R Lütticken; A Podbielski
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

Review 8.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

9.  Progress toward a group B streptococcal vaccine.

Authors:  Joon Young Song; Jae Hyang Lim; Sangyong Lim; Zhi Yong; Ho Seong Seo
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.